G1T38 is a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Preclinical data presented at the American Association for Cancer Research 2016 Annual Meeting and published in Molecular Cancer Research and Oncotarget demonstrated G1T38’s differentiation from other CDK4/6 inhibitors in development.

A Phase 1 study has recently been completed in 75 healthy subjects; G1T38 was well-tolerated with no grade 3/4 adverse events. G1T38 is currently being evaluated in combination with Faslodex® in a Phase 1b/2a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.